GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1223-1229

  Eicke, Nicola ^a   Günthert, Andreas R ^a   Emons, Günter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

EGF; Endometrial cancer; GnRH II; Ovarian cancer; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GNRHR PROTEIN, HUMAN; GNRHR2 PROTEIN, HUMAN; GONADORELIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN C FOS; PROTEIN TYROSINE PHOSPHATASE; TRIPTORELIN;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; SIGNAL TRANSDUCTION;

ENDOMETRIAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MAP KINASE KINASE KINASES; OVARIAN NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, LHRH; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIPTORELIN;

EID: 33847739428     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1223     Document Type: Article

References (28)

1. Gründker C, Günthert AR, Westphalen S and Emons G: Biology of the gonadotropin-releasing hormone (GnRH) system in gynecological cancers. Eur J Endocrinol 146: 1-14, 2002. (Pubitemid 34126412)
2. Emons G, Ortmann O, Becker M, et al: High affinity binding and direct antiproliferative effects of LHRH analogs in human ovarian cancer cell lines. Cancer Res 54: 5439-5446, 1993. (Pubitemid 23342164)
3. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analoges in human endometrial cancer cell lines. J Endocrinol Metab 77: 1458-1464, 1993. (Pubitemid 24000896)
4. Irmer G, Bürger C, Müller R, et al: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
5. Emons G, Ortmann O, Schulz KD and Schally AV: Growth inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab 8: 355-362, 1997. (Pubitemid 28034420)
6. Gründker C, Völker P, Schulz KD and Emons G: Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibits EGF-induced c-fos expresssion in human gynecological cancers. Gynecol Oncol 78: 194-202, 2000. (Pubitemid 30650353)
7. Gründker C, Völker P and Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein αi-mediated activation of phosphotyrosine phosphatase. Endocrinology 142: 2369-2380, 2003. (Pubitemid 32473092)
8. Emons G, Müller V, Ortmann O, et al: Luteinizing hormone-releasing hormone agonist triptorelin antagonises signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 9: 1129-1137, 1996. (Pubitemid 26393305)
9. Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B and Emons G: Antiproliferative effects of the GnRH antagonists cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151: 141-149, 2004. (Pubitemid 39117377)
10. Gründker C, Günthert AR, Millar RP and Emons G: Expression of gonadotropin releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87: 1427-1430, 2002.
11. Völker P, Gründker C, Schmidt O, Schulz KD and Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation and correlation with direct antiproliferative activity of LHRH analogues. Am J Obstet Gynecol 86: 171-179, 2002. (Pubitemid 34165428)
12. Nishida M, Kasahara K, Kaneko M and Iwasaki H: Establishment of a new endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynaecol Jpn 37: 1103-1111, 1985.
13. Kuramoto H, Tamura S and Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114: 1012-1019, 1972.
14. Simon WE, Albrecht M, Hänsel M, Dietel M and Hölzel F: Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70: 839-845, 1983.
15. Soule HD, Vasques J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
16. Harder KW, Owen P, Wong LK, Aebersold R, Clark-Lewis I and Jirik FR: Characterisation and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase β (HPTPβ) using synthetic phosphopeptides. Biochem J 298: 395-401, 1994.
17. Daum G, Solca F, Diltz CD, Zhao Z, Cool DE and Fischer EH: A general peptide substrate for protein tyrosine phosphatases. Anal Biochem 211: 50-54, 1993.
18. Eicke N, Günthert AR, Viereck V, et al: GnRH-II receptor-like antigenicity in human placenta and in cancers of human reproductive organs. Eur J Endocrinol 153: 605-612, 2005.
19. Günthert AR, Gründker C, Olota A, Läsche J, Eicke N and Emons G: Analogs of gonadotropin-releasing hormone I (GnRH-I) and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-Tamoxifen. Eur J Endocrinol 153: 613-625, 2005.
20. Millar R, Lowe S, Conklin D, et al: A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98: 9636-9641, 2001.
21. Neill JD, Duck LW, Sellers JC and Musgrove LC: A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 282: 1012-1018, 2001.
22. Neill JD, Musgrove LC and Duck LW: Newly recognized GnRH-receptor: function and relative role. Trends Endocrinol Metab 15: 383-392, 2004.
23. Millar RP, Conklin D, Lofton-Day C, et al: A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of the antisense transcript. J Endocrinol 162: 117-126, 1999.
24. Millar RP: GnRH II and type II GnRH receptors. Trends Endocrinol Metab 14: 35-43, 2003.
25. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR and Millar RP: A transcriptionally active human type II gonadotropin- releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144: 423-436, 2003.
26. Ling K, Wang P, Zhao J, et al: Five transmembrane domains appear sufficient for a G protein-coupled receptor: functional five-transmembrane domain chemokine receptor. Proc Natl Acad Sci USA 96: 7922-7927, 1999.
27. Van Biljon W, Wykes S, Scherer S, Krawetz SA and Hapgood J: Type II gonadotropin-releasing hormone receptor transcripts in human sperm. Biol Reprod 67: 1741-1749, 2002.
28. Kim KY, Choi KC, Auersperg N and Leung PC: Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13: 211-220, 2006.